Cargando…
Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP)
INTRODUCTION: Post-marketing surveillance activities (namely pharmacovigilance) are crucial to favor the early detection of unexpected adverse events (AEs) and/or serious adverse reactions (SAEs). Indeed, spontaneous reporting of AEs has been demonstrated to underestimate the number of events in dif...
Autores principales: | Palleria, Caterina, Iannone, Luigi, Leporini, Christian, Citraro, Rita, Manti, Antonia, Caminiti, Maurizio, Gigliotti, Pietro, Grembiale, Rosa Daniela, L’Andolina, Massimo, Muccari, Giuseppe, Naturale, Maria Diana, Olivo, Domenico, Pagano Mariano, Giuseppa, Pellegrini, Roberta, Varcasia, Giuseppe, Abdalla, Karim, Russo, Emilio, Ursini, Francesco, De Sarro, Giovambattista |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200211/ https://www.ncbi.nlm.nih.gov/pubmed/30356301 http://dx.doi.org/10.1371/journal.pone.0205134 |
Ejemplares similares
-
Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region
por: Gagliardi, Agnese, et al.
Publicado: (2022) -
Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study
por: Tallarico, Martina, et al.
Publicado: (2022) -
Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
por: Giofrè, Chiara, et al.
Publicado: (2013) -
Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study
por: Iannone, Luigi Francesco, et al.
Publicado: (2020) -
Pharmacovigilance in Calabria (Italy): Local experiences resonate international relevance
por: Russo, Emilio, et al.
Publicado: (2013)